Business

Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development

SOUTH SAN FRANCISCO, Calif., Feb. 5, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing

articleSutro Biopharma, Inc.February 5, 20204/company/sutro-biopharma/news/sutro-biopharma-expands-senior-management-team-with-the-appointments-of-vice-president-of-immunobiology-and-vice-president-of-business-development
Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development

About this update from Sutro Biopharma, Inc.

[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Feb. 5, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the expansion of its senior management team with the appointments of Kristin Bedard, Ph.D., as Vice President of Immunobiology, and Brunilda Shtylla as Vice President of Business Development.\n\"Kristin brings a proven track record of advancing novel therapies into the clinic, with expertise in immuno-oncology and demonstrated scientific leadership. Brunilda has deep experience in the biopharma industry and brings strategic evaluation, analysis and negotiation skills to Sutro to support business development opportunities,\" said Bill Newell, Sutro's Chief Executive Officer. \"These appointments provide an expanded breadth of key scientific and business expertise to drive the ongoing advancement of our clinical pipeline and partnerships utilizing our technology.\"\nDr. Bedard previously held leadership positions at Kineta, most recently as Chief Scientific Officer, Immuno-oncology and Senior Vice President, Discovery and formerly as Vice President of R&D and Head of Virology. She is the co-inventor of fifteen filed U.S. patent applications for novel classes of antivirals, adjuvants, immune agonists and their corresponding methods of identification. Dr. Bedard received her B.S. from Pennsylvania State University and earned her Ph.D. from University of California, Irvine.\nMs. Shtylla worked as an independent consultant since 2012, which included consulting for Genentech since 2013. Prior to this, she held numerous positions at Lifescan, a Johnson & Johnson company, including Associate Director of Partnerships and Product Director, U.S. Brand Marketing. Previously, Ms. Shtylla held roles in Business Development, Technology Transfer, Sales & Operations Planning, Investment Banking and Finance. She received her B.S. from Wayne State University, a M.S. in Mathematics from Youngstown State University and an M.B.A. from Stanford Graduate School of Business.\nAbout Sutro Biopharma Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein eng...

More updates from Sutro Biopharma, Inc.